TY - JOUR
AU - Rosas, Ivan O.
AU - Bräu, Norbert
AU - Waters, Michael
AU - Go, Ronaldo C
AU - Malhotra, Atul
AU - Hunter, Bradley D
AU - Bhagani, Sanjay
AU - Skiest, Daniel
AU - Savic, Sinisa
AU - Douglas, Ivor S
AU - Garcia-Diaz, Julia
AU - Aziz, Mariam S
AU - Cooper, Nicola J.
AU - Youngstein, Taryn
AU - Sorbo, Lorenzo Del
AU - Zerda, David J De La
AU - Ustianowski, Andrew
AU - Gracian, Antonio Cubillo
AU - Blyth, Kevin G.
AU - Carratalà, Jordi
AU - François, Bruno
AU - Benfield, Thomas
AU - Haslem, Derrick
AU - Bonfanti, Paolo
AU - van der Leest, Cor H
AU - Rohatgi, Nidhi
AU - Wiese, Lothar
AU - Luyt, Charles Edouard
AU - Bauer, Rebecca N
AU - Cai, Fang
AU - Lee, Ivan T
AU - Matharu, Balpreet
AU - Metcalf, Louis
AU - Wildum, Steffen
AU - Graham, Emily
AU - Tsai, Larry
AU - Bao, Min
PY - 2022
DA - May
TI - Tocilizumab in patients hospitalised with COVID-19 pneumonia: efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
JO - EClinicalMedicine
VL - 47
DO - http://dx.doi.org/10.1016/j.eclinm.2022.101409
AB - Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. Therefore, the efficacy and safety of tocilizumab in COVID-19 beyond day 28 and its impact on Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) clearance and antibody response in COVACTA were investigated.
PB - Elsevier
UR - http://eprints.gla.ac.uk/270777/
KW - Coronavirus (COVID-19)
KW - Hospital care
ER